Introduction
Pharmacotherapy, when optimal, is expected to restore a pathophysiological abnormality to normal. An antihypertensive drug should lower a patient's abnormally high blood pressure (BP) to normal, but should not lower the BP below normal, although it is difficult to assess what normal BP is in a given individual.
Several kinds of antihypertensive drugs having differing pharmacological properties are now available for clinical use. Over 70% of the hypertensive subjects in Japan are treated with calcium (Ca) entry blockers, although the use of angiotensin-converting enzyme (ACE) inhibitors is increasing. 1 Although there has been a gradual decrease in the use of adrenergic ␤-receptor blockers, these drugs are still widely used as antihypertensive treatment in Japan. 1 Correspondence: Dr Yutaka Imai, The Second Department of Internal Medicine, Tohoku University School of Medicine, 1-1 Seiryomachi, Sendai, 980-77, Japan Received 27 April 1998; revised 22 June 1998; accepted 16 July 1998 characteristic among the drugs. The critical daytime systolic ambulatory BP below which a hypotensive effect was not observed was extrapolated to 128, 127 and 124 mm Hg with nilvadipine, amlodipine and bisoprolol, respectively, while that with lisinopril was 97 mm Hg. The slope of the correlation coefficient between basal daytime ambulatory systolic BP and hypotensive effect with lisinopril was significantly smaller than those with the other drugs (P Ͻ 0.0001). The slope for the relationship between night-time ambulatory systolic BP and the hypotensive effect with bisoprolol was the steepest (P Ͻ 0.0001). Antihypertensive drugs with different pharmacological properties exhibited differing hypotensive effects on the basal ambulatory BP. Such differences in efficacy of the drugs on the basal ambulatory BP may reflect adverse effects of the drugs and the prognosis of hypertension.
The present study was designed to examine how antihypertensive drugs with differing pharmacological properties affect the BP. We looked at the effect of antihypertensive drugs on differential ambulatory BP levels and on the nocturnal BP. Ambulatory BP monitoring has several advantages over traditional casual (clinic) BP measurement. Specifically, ambulatory BP monitoring is useful in identifying patients with 'white-coat', 'isolated clinic' or 'false' hypertension, to exclude the placebo response, and to assess antihypertensive effects throughout the day including hypotensive effects at night. 
Materials and methods
In 1994, the Research Group for Evaluation of the Effect of Drug Treatment on Hypertension and Other Chronic Disease Conditions, supported by the Japanese Ministry of Health and Welfare, was established. The Japanese Ambulatory Pressure-ANtihypertensive Effects SEarching (JAPANESE) study group was established as a subcommittee. The JAPANESE study group collected ambulatory BP and clinic BP measurements obtained both in con-trol and treatment periods from institutions throughout Japan. The drugs used were those evaluated in phase II, III or IV clinical trials on the basis of the guidelines for clinical trials of antihypertensive drugs of the Ministry of Health and Welfare, Japan, where at least a 4-week run-in washout period or a 2-week placebo control period is necessary. An inclusion criterion of the guidelines required that the average of the last two measurements of clinic BP is у160 mm Hg and/or 95 mm Hg. However, the subjects whose average clinic BP is у150 mm Hg and 90 mm Hg were usually included on the basis of the decision of the management committee for drug trial.
The dosage titration of each drug was based on the protocol of the trial for each drug. The medication dosage increased on the basis of clinic BP readings. If clinic BP did not decrease by more than 20/10 mm Hg or decrease to 149/89 mm Hg or lower within 2-4 weeks of treatment, the dosage increased gradually to the preset maximum dose.
The drugs were nilvadipine (195 cases), amlodipine (75), lisinopril (80) and bisoprolol (49). Patients were in monotherapy during the treatment period. The background of the subjects to whom these antihypertensive drugs were administered is shown in Table 1 . Amlodipine, lisinopril, and bisoprolol were administered once daily in the morning after breakfast; nilvadipine was taken twice daily after breakfast and again after supper. The dose administered and the duration of treatment is shown in Table 1 .
The clinic BP was measured between 09.00 and 13.00 by the standard auscultatory method, using a mercury sphygmomanometer. Thus, the clinic BP measurements during the treatment period were done 2-7 h after the morning dose. The subjects were screened for hypertension on the basis of the clinic BP, which was measured at least three times during run-in placebo period or wash-out period. The clinic BP was measured twice on each occasion in the sitting position, and the average of two measurements was used as the clinic BP for that day. The average of the last two clinic BPs was considered to be the basal clinic BP. Clinic BP during treatment defined as the average of two clinic BPs on two separate occasions was measured shortly before or after ambulatory BP monitoring.
Ambulatory BP was monitored using fully automatic devices, including the Colin ABPM 630 (Nippon Colin, Komaki, Japan) or the A & D TM2421 (A & D, Tokyo, Japan). Both devices were validated by one of the authors (YI) and reported previously The same device was applied in the same subject in the control and treatment periods. Ambulatory BP was monitored in the treatment period when the sufficient effect was observed (р149/89 mm Hg or decrease in BP у20/10 mm Hg) in the clinic BP or the maximum dose was used. The measurement interval for ambulatory BP monitoring was not standardised. However, BP was measured at least every 30 min for 24 h. Artifactual readings were edited out according to previously described criteria. 5 'Nighttime' was defined as 23.00 to 05.00 h and 'daytime' as 08.00 to 21.00 h.
Drug compliance was examined by each physician in each institution using pill count. When the subjects were defined as non-compliant, these were not registered in the present database.
Findings are expressed as mean ± s.d. Differences were analysed by the Student's t-test. The slope of the correlation equation between basal ambulatory BP and hypotensive effects and intercept with the X-axis were compared among the drugs by analysis of covariance using the SAS GLM procedure. 6 A level of P Ͻ 0.05 was accepted as statistically significant.
Results
All four antihypertensive drugs significantly reduced the clinic and the ambulatory BP ( Table 2 ). The hypotensive effects of drug treatment were comparable for the different antihypertensive drugs. The hypotensive effects determined by clinic BP were significantly greater than those determined by ambulatory BP (P Ͻ 0.001, in all drugs).
The relationships between basal daytime ambulatory BP and the hypotensive effect of each drug are illustrated in Figure 1 . With each drug, the hypotensive effect was greater the higher the initial daytime ambulatory BP. The intercept with the X-axis, ie, the hypothetical critical daytime ambulatory systolic BP (SBP) level below which a hypotensive effect was not observed, was 128 mm Hg (95% confidence interval (95%CI):120-133) with nilvadipine, 127 mm Hg (111-136) with amlodipine and 124 mm Hg (72-138) with bisoprolol, while that with lisinopril was 97 mm Hg (56-125). The 'r' value for lisinopril was 0.27 with a 'P' value of 0.016, much lower than for other drugs. Thus, although the response to lisinopril did not correlate as well with the basal SBP as it did with the other drugs, the slope of the corre- -121) ). This suggests the possibility that bisoprolol reduces the high nocturnal ambulatory SBP due to increased cardiovascular tone during sleep and has a lesser effect on low nocturnal ambulatory SBP as compared with the other three drugs. Such a tendency was also observed in nocturnal ambulatory diastolic BP (DBP), although the slopes were not significantly different among the drugs.
Discussion
All four antihypertensive drugs studied, including the Ca entry blockers (nilvadipine and amlodipine), the ␤-blocker (bisoprolol) and the ACE inhibitor (lisinopril), reduced both the clinic and the ambulatory BPs. With all of these drugs, the lower the basal ambulatory BP, the less was the hypotensive effect. This agrees with previous studies, showing that antihypertensive therapy had almost no effect on the 24-h BP in individuals with hypertensive clinic readings but with normal ambulatory BP measurements (isolated clinic hypertension).
2,7-11 However, we also observed a quantitative difference in this characteristic among antihypertensive drugs. In the present study, it is hypothesised that lisinopril lowered the daytime ambulatory SBP in subjects with a low daytime ambulatory SBP to a greater extent than the Ca entry blockers or bisoprolol.
Ashida et al 12 and Herpin et al 13 found that ACE inhibitors, but not Ca entry blockers, lowered the ambulatory BP in subjects with white coat hypertension, which is characterised by a high clinic BP and a normal ambulatory BP. One then asks: does this characteristic of ACE inhibitors have any clinical significance? In patients with normal ambulatory BP, antihypertensive treatment is not thought of as having any benefit, and the patients may develop side effects. 10 However, to discuss such a problem, the level of ambulatory BP that defines normotension and hypertension must be considered. Reference values for ambulatory BP must be derived from population-based prospective studies of the prognosis of hypertension. To our knowledge, such reference values were derived only from the Ohasama Study in Japan. 14, 15 Based on this study, it is suggested that an ambulatory BP у135/80 mm Hg is defined as hypertension. The lowest relative hazard is observed with a 24-h ambulatory BP level of 111-117 mm Hg systolic and Ͻ68 mm Hg diastolic. 15 The intercept with the X-axis in the relationship between basal 24-h ambulatory SBP and the hypotensive effect was 117 mm Hg or higher for Ca entry blockers and bisoprolol but 105 mm Hg for lisinopril (Figure 1 ). This suggests that the BP-lowering effect of lisinopril in subjects with a relatively low ambulatory BP does not necessarily cause excessive hypotension, but rather maintains an optimal BP level. This may partly explain the results of several interventional studies in which ACE inhibitors effectively improved the prognosis of hypertension 16 and caused a regression of cardiac hypertrophy 17 as compared with other kinds of antihypertensive drugs.
Quantitative differences in the effects of antihypertensive drugs on the nocturnal ambulatory BP were also confirmed in the present study. Bisoprolol, a selective ␤ 1 -adrenoceptor blocker without sympathomimetic action, had a minimal effect on the nocturnal BP in subjects with a low night-time ambulatory BP. Because an excessive reduction in BP induced by antihypertensive drugs can potentially lead to ischaemic cerebrovascular 18, 19 and cardiovascular complications, 20 the minimal effect of bisoprolol may make it beneficial in treating hypertensive patients with a low nocturnal BP, especially in treating those patients with cerebrovascular [21] [22] [23] and cardiovascular 20 target organ damage. The minimal nocturnal effect of bisoprolol on relatively low night-time ambulatory BP may have been related to a relatively short duration of action of this drug. However, this possibility is unlikely because bisoprolol has been shown to control the ambulatory BP throughout a 24-h period. 24, 25 Furthermore, bisopro- lol tended to lower the relatively high basal nighttime ambulatory SBP more than Ca entry blockers and lisinopril, suggesting that once-a-day administration of bisoprolol in the morning is effective throughout a 24-h period. The possibility remains that the minimal effect of bisoprolol on relatively low night-time ambulatory BP is due to decreased cardiovascular sympathetic activity while asleep in such patients, while sympathetic activity may be greater in people with a higher nocturnal BP. Basing the antihypertensive therapy on the clinic BP can induce an overestimation [26] [27] [28] [29] or underestimation of its efficacy mainly due to white-coat effect. [29] [30] [31] [32] The prevalence of isolated clinic hypertension (white coat hypertension) in drug trials seems to be extremely high. 33 In the present study, 10.3% of subjects with clinic SBP у150 and DBP у90 mm Hg had isolated clinic hypertension when normotension was defined as ambulatory SBP Ͻ135 and DBP Ͻ80 mm Hg. There are a number of possible limitations to the present study. Since the study was done retrospectively and collected data of a number of different trials were analysed, the subjects in each group of treatment were not homogenous; eg, subjects in the amlodipine group are about 10 years older and many more women had been enrolled. The critical BP levels below which hypotensive effect was not observed were hypothetical ones which were obtained from the extrapolation of the linear regression equation. In fact, there are no or a very limited number of patients with low daytime SBP. For instance, for lisinopril there are no patients with daytime SBP Ͻ120 mm Hg (Figure 1 ). Further measurements are necessary to realise the relationship between basal ambulatory BP and the hypotensive effect of the drug. The JAPANESE study group is now gathering further data. Although the same device was applied before and during treatment periods in an individual, the different types of device for ambulatory BP monitoring were used in the different institutions. However, we have previously reported that the mean difference of BP values between the device and auscultatory method was not different between two types of device. 3, 4 Thus, the difference in the type of device may not have such an influence on the results. Although the reproducibility of ambulatory BP measurements are highly evaluated in several previous reports, [34] [35] [36] regression to the mean has still been observed in this method; 34, 37 ie, repeated ambulatory BP monitoring gave lower results on a second reading, if higher results were observed during the first reading. However, this statistical phenomenon would be observed in all groups of treatment. Therefore, the quantitative difference of drug effect among drugs was not only explained by regression to the mean.
Antihypertensive drugs with different pharmacological properties exhibited differing hypotensive effects on the basal ambulatory BP. Such differences in efficacy of the drugs on the basal ambulatory BP may reflect the adverse effect of drugs and the prognosis of hypertension.
